HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) but has reduced the price target from $35 to $33.

January 16, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
EyePoint Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., but the price target is lowered from $35 to $33.
While the Buy rating reaffirms confidence in EyePoint Pharmaceuticals, the reduction in price target could suggest a more conservative outlook on the company's future performance. This may lead to mixed reactions in the short term, as the maintained Buy rating could be seen as positive, but the lowered price target might raise concerns among investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100